InMed Pharmaceuticals Inc. (INM) Revenue History
Annual and quarterly revenue from 2001 to present
INM Revenue Over Time (2001–2025)
INM Revenue Growth History
7 of 14 years with positive growth- FY2001 revenue growth
- N/A
- FY2002 revenue growth
- +463.8%
- FY2003 revenue growth
- +1248.0%
- FY2004 revenue growth
- +1027.4%
- FY2005 revenue growth
- +102.3%
- FY2006 revenue growth
- -34.8%
- FY2007 revenue growth
- -70.1%
- FY2008 revenue growth
- -24.5%
- FY2009 revenue growth
- -73.0%
- FY2010 revenue growth
- -52.8%
- FY2011 revenue growth
- -50.1%
- FY2012 revenue growth
- -100.0%
- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- +279.6%
- FY2024 revenue growth
- +11.2%
- FY2025 revenue growth
- +7.5%
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $659.8M | +52203.4% |
| Q2 2026 | $1.1M | +1.2% |
| Q1 2026 | $1.1M | -11.4% |
| Q4 2025 | $1.8M | +38.5% |
| Q3 2025 | $1.3M | +7.6% |
| Q2 2025 | $1.1M | -10.4% |
| Q1 2025 | $1.3M | +40.2% |
| Q4 2024 | $1.3M | -58.1% |
Multi-year avg. share of annual revenue by fiscal quarter
INM Revenue Analysis (2001–2025)
Current Revenue & Growth
As of June 21, 2026, InMed Pharmaceuticals Inc. (INM) generated trailing twelve-month (TTM) revenue of $663.9 million, reflecting explosive growth of +52203.4% year-over-year. The most recent quarter (Q3 2026) recorded $659.8 million in revenue, up 58532.1% sequentially.
Historical Growth Trajectory
INM's historical revenue data shows a 3-year CAGR of +65.5%. InMed Pharmaceuticals Inc.'s highest annual revenue of $4.9 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including YCBD (+2.0% YoY), ATAI (+87.2% YoY), and SNDL (+1.1% YoY) — INM has outperformed the peer group in revenue growth. Compare INM vs YCBD →
INM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| INMCurrent | $664M | +52203.4% | - | -160.2% | |
 YCBD | $19M | +2.0% | -14.5% | -11.3% | |
 ATAI | $4M | +87.2% | - | -2439.7% | |
 SNDL | $946M | +1.1% | +73.1% | -0.5% |
INM Historical Revenue Data (2001–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.9M | +7.5% | $1.7M | 34.5% | $-7,917,995 | -160.2% |
| 2024 | $4.6M | +11.2% | $1.1M | 23.9% | $-8,134,430 | -176.9% |
| 2023 | $4.1M | +279.6% | $1.4M | 33.9% | $-8,378,787 | -202.6% |
| 2022 | $1.1M | - | $544K | 49.9% | $-13,791,756 | -1266.0% |
| 2021 | $0 | - | $0 | - | $-12,171,142 | - |
| 2020 | $0 | - | $-183,090 | - | $-9,150,862 | - |
| 2019 | $0 | - | $-93,940 | - | $-10,358,873 | - |
| 2018 | $0 | - | $-92,777 | - | $-6,778,130 | - |
| 2017 | $0 | - | $0 | - | $-3,439,445 | - |
| 2016 | $0 | - | $0 | - | $-1,837,361 | - |
| 2015 | $0 | - | $0 | - | $-3,454,625 | - |
| 2014 | $0 | - | $0 | - | $-1,150,478 | - |
| 2013 | $0 | - | $0 | - | $-49,186 | - |
| 2012 | $0 | -100.0% | $0 | - | $-168,719 | - |
| 2011 | $40K | -50.1% | $12K | 31.0% | $-387,556 | -977.2% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INM — Frequently Asked Questions
Quick answers to the most common questions about buying INM stock.
Is INM's revenue growth accelerating or slowing?
INM revenue growth is accelerating. TTM revenue reached $664M, up +52203.4% year-over-year — ahead of the 5-year CAGR of N/A. This indicates the business is expanding faster than its historical baseline.
What is INM's revenue history from 2001 to 2026?
InMed Pharmaceuticals Inc. (INM) revenue history spans 2001 to 2026. TTM revenue as of 2026 is $664M, growing at +52203.4% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is INM's long-term revenue growth rate (CAGR)?
InMed Pharmaceuticals Inc.'s 5-year revenue CAGR of N/A reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +52203.4% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for INM.
Why does INM's quarterly revenue fluctuate?
INM quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. InMed Pharmaceuticals Inc.'s revenue data from 2001 to 2026 shows full historical quarterly detail on this page.
How is INM's revenue distributed by segment?
INM reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does INM's revenue compare to industry peers?
InMed Pharmaceuticals Inc. (INM) with TTM revenue of $664M and +52203.4% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.